A summary of the key clinical and safety data for olaparib monotherapy and combinations in patients with metastatic castration-resistant prostate cancer and a BRCA mutation, to help you with treatment decision-making.
The advent of PSMA-targeted radioligand therapies and bispecific T-cell engagers has provided new hope for patients with metastatic castration-resistant prostate cancer. Explore the latest evidence.
Raised YKL-40 levels are associated with an increased risk for obesity-related and gastrointestinal cancers, particularly liver cancer, in people with type 2 diabetes.
Learn about the rationale for using PARP inhibitors in the neoadjuvant treatment of various cancers with homologous recombination repair deficiency, as well as the ongoing clinical trials and future directions.
Offering targeted screening based on a high polygenic risk score led to the detection of a high proportion of clinically significant prostate cancer in the BARCODE1 trial.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.
In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.
Please note, this webinar is not intended for healthcare professionals based in the US and UK.
Fatal outcomes in three cases, despite aggressive treatment, emphasize the poor prognosis of fulminant myocarditis related to immune checkpoint inhibitor therapy.
A patient treated with carboplatin for stage I seminoma developed hematuria and acute kidney injury. It is crucial to recognize this rare but serious complication and start treatment promptly to prevent further kidney damage.
A man receiving abiraterone for prostate cancer developed severe hypokalemia, which led to polymorphic ventricular tachycardia and cardiac arrest. It is important to consider iatrogenic causes in cases of arrhythmia.
PSMA-RADS version 1, introduced by Rowe et al. in 2017, provides a framework for classifying PSMA-targeted PET scans and individual findings based on their likelihood of representing prostate cancer. The system was optimized for findings outside …
Radical prostatectomy (RP) is a common treatment modality in for localized prostate cancer, however a subset of patients with localized disease are at risk of biochemical recurrence (BCR) after RP. Among high-risk patients, BCR rates can be …
Renal cell carcinoma (RCC) is the most prevalent primary malignancy of the kidney, accounting for nearly 90% of all renal cancers [ 1 , 2 ]. The incidence of RCC has been steadily rising on a global scale, partly owing to the extensive utilization …
Prostate cancer (PC) is the most frequently diagnosed cancer in men, with significant incidence and mortality rates [ 1 ]. In 2022, PC accounted for 7.3% of all newly diagnosed cancers globally, affecting 1.5 million men and causing 400,000 deaths …
An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.
Prostate cancer typically starts as a localised or locally advanced disease affecting the prostate gland and its anatomical surroundings [ 1 ]. However, distant metastases can also be present at first diagnosis or develop over time [ 1 – 3 ].
High mobility group protein 2 (HMGA2) is an essential component of the enhanceosome that regulates gene transcription during organ development, and its re-expression in adult tissues is often linked to tumor formation and progression. To …
Radical prostatectomy (RP) is a common treatment modality in for localized prostate cancer, however a subset of patients with localized disease are at risk of biochemical recurrence (BCR) after RP. Among high-risk patients, BCR rates can be …
Bladder cancer is the 10 th most common cancer worldwide with an estimated 573,000 new cases and 213,000 deaths in 2020, showing higher incidence rates in men and in developed regions such as Europe. In Europe, bladder cancer represents one of the …
